ADMA Biologics Inc (ADMA): Price and Financial Metrics


ADMA Biologics Inc (ADMA): $2.04

-0.01 (-0.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ADMA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ADMA POWR Grades


  • Growth is the dimension where ADMA ranks best; there it ranks ahead of 83.22% of US stocks.
  • The strongest trend for ADMA is in Value, which has been heading down over the past 179 days.
  • ADMA's current lowest rank is in the Quality metric (where it is better than 0.32% of US stocks).

ADMA Stock Summary

  • ADMA has a higher market value than 30.38% of US stocks; more precisely, its current market capitalization is $358,534,246.
  • Revenue growth over the past 12 months for Adma Biologics Inc comes in at 91.72%, a number that bests 91.07% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ADMA comes in at -33.78% -- higher than that of only 11.86% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Adma Biologics Inc are ACB, TTMI, BCOR, IDXG, and CMCO.
  • ADMA's SEC filings can be seen here. And to visit Adma Biologics Inc's official web site, go to www.admabiologics.com.

ADMA Valuation Summary

  • ADMA's price/sales ratio is 3.1; this is 18.42% lower than that of the median Healthcare stock.
  • ADMA's EV/EBIT ratio has moved up 2.2 over the prior 96 months.
  • Over the past 96 months, ADMA's price/sales ratio has gone down 41.8.

Below are key valuation metrics over time for ADMA.

Stock Date P/S P/B P/E EV/EBIT
ADMA 2021-08-31 3.1 1.6 -2.4 -3.8
ADMA 2021-08-30 3.0 1.6 -2.4 -3.7
ADMA 2021-08-27 3.2 1.6 -2.5 -3.9
ADMA 2021-08-26 3.2 1.6 -2.5 -3.9
ADMA 2021-08-25 3.2 1.7 -2.5 -3.9
ADMA 2021-08-24 3.1 1.6 -2.5 -3.8

ADMA Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -186.96%.
  • Its year over year net cashflow from operations growth rate is now at -27.77%.
  • Its 5 year revenue growth rate is now at 361.89%.
Over the past 67 months, ADMA's revenue has gone up $60,717,432.

The table below shows ADMA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 68.51584 -111.1232 -74.40597
2021-06-30 58.11165 -121.5629 -73.61047
2021-03-31 48.06866 -110.5851 -74.88326
2020-12-31 42.21978 -102.003 -75.74855
2020-09-30 40.30074 -89.43556 -66.9018
2020-06-30 37.24689 -89.2138 -61.42281

ADMA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ADMA has a Quality Grade of F, ranking ahead of 0.06% of graded US stocks.
  • ADMA's asset turnover comes in at 0.268 -- ranking 168th of 682 Pharmaceutical Products stocks.
  • NOVN, ARNA, and ZYNE are the stocks whose asset turnover ratios are most correlated with ADMA.

The table below shows ADMA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.268 -0.163 -0.264
2021-03-31 0.233 -0.295 -0.291
2020-12-31 0.211 -0.452 -0.318
2020-09-30 0.224 -0.337 -0.296
2020-06-30 0.223 -0.341 -0.290
2020-03-31 0.233 -0.303 -0.279

ADMA Price Target

For more insight on analysts targets of ADMA, see our ADMA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.67 Average Broker Recommendation 1.4 (Strong Buy)

ADMA Stock Price Chart Interactive Chart >

Price chart for ADMA

ADMA Price/Volume Stats

Current price $2.04 52-week high $2.15
Prev. close $2.05 52-week low $1.01
Day low $1.99 Volume 1,529,200
Day high $2.07 Avg. volume 2,380,754
50-day MA $1.85 Dividend yield N/A
200-day MA $1.50 Market Cap 399.68M

ADMA Biologics Inc (ADMA) Company Bio


ADMA Biologics, Inc. develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The company was founded in 2004 and is based in Ramsey, New Jersey.


ADMA Latest News Stream


Event/Time News Detail
Loading, please wait...

ADMA Latest Social Stream


Loading social stream, please wait...

View Full ADMA Social Stream

Latest ADMA News From Around the Web

Below are the latest news stories about Adma Biologics Inc that investors may wish to consider to help them evaluate ADMA as an investment opportunity.

ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update

Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Inception Full Year 2021 Preliminary Unaudited Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year 2020 Company Reiterates All Previously Provided Financial Targets Ongoing Strategic Review & Debt Refinancing Activities RAMSEY, N.J. and BOCA RATON, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or th

Yahoo | January 19, 2022

ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SC

FDA approval positions Company to meet or exceed target of ten or more FDA-licensed plasma collection centers by year-end 2023RAMSEY, N.J. and BOCA RATON, Fla. and GOOSE CREEK, S.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration (“FDA”) approval for its f

Yahoo | January 18, 2022

ADMA Biologics (NASDAQ:ADMA) investors are sitting on a loss of 72% if they invested five years ago

While not a mind-blowing move, it is good to see that the ADMA Biologics, Inc. ( NASDAQ:ADMA ) share price has gained...

Yahoo | January 17, 2022

Hikari Power Ltd Buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Sells ...

Tokyo, M0, based Investment company Hikari Power Ltd (Current Portfolio) buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Jack Henry & Associates Inc, Parker Hannifin Corp, sells Anheuser-Busch InBev SA/NV, The Kraft Heinz Co, Amarin Corp PLC, ADMA Biologics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Hikari Power Ltd.

Yahoo | January 12, 2022

These 2 “Strong Buy” Penny Stocks Are Poised to Take Off, Says Raymond James

Let’s talk about penny stocks. These are equities that trade for less than $5 per share, the very bottom of the price range. While they are priced that low for a reason – and the reasons may vary – low price in itself doesn’t mean that the stock’s fundamentals are sour. Smart investors can find some true bargains among the penny stocks, and set themselves up for outsized gains.

Michael Marcus on TipRanks | December 29, 2021

Read More 'ADMA' Stories Here

ADMA Price Returns

1-mo 2.51%
3-mo N/A
6-mo 44.68%
1-year 15.91%
3-year -56.60%
5-year -44.57%
YTD 44.68%
2021 -27.69%
2020 -51.25%
2019 67.36%
2018 -25.55%
2017 -37.30%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6731 seconds.